BIOMAT Database Logo BIOMAT Database Logo

Angiotensin infusion test. 1965

A G Hocken, and R M Kark

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006974 Hypertension, Malignant A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction. Malignant Hypertension
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

A G Hocken, and R M Kark
Angiotensin infusion test.
January 1968, Canadian Medical Association journal,
A G Hocken, and R M Kark
ANGIOTENSIN-INFUSION TEST.
July 1965, Lancet (London, England),
A G Hocken, and R M Kark
The angiotensin infusion test.
August 1966, The Journal of urology,
A G Hocken, and R M Kark
Angiotensin infusion test in hypertension.
May 1966, American heart journal,
A G Hocken, and R M Kark
[Angiotensin II analogue infusion test].
April 1997, Nihon rinsho. Japanese journal of clinical medicine,
A G Hocken, and R M Kark
[Angiotensin infusion test in liver cirrhosis].
January 1971, Polskie Archiwum Medycyny Wewnetrznej,
A G Hocken, and R M Kark
Angiotensin infusion test in arterial hypertension.
September 1966, Acta medica Scandinavica,
A G Hocken, and R M Kark
The angiotensin infusion test: preliminary experience.
January 1966, Lahey Clinic Foundation bulletin,
A G Hocken, and R M Kark
THE ANGIOTENSIN INFUSION TEST FOR RENOVASCULAR HYPERTENSION.
March 1965, Connecticut medicine,
A G Hocken, and R M Kark
[Diagnostic significance of the angiotensin infusion test].
October 1968, Revista medica de Chile,
Copied contents to your clipboard!